DEFA14A: Coherus BioSciences Outlines Strategic Transformation and Pipeline Progress at J.P. Morgan Healthcare Conference

Coherus BioSciences details its strategic shift towards innovative oncology, highlighted by the UDENYCA franchise divestiture and advancements in its immuno-oncology pipeline.

Summary

• Coherus BioSciences presented at the 43rd Annual J.P. Morgan Healthcare Conference in January 2025, outlining its strategic transformation.
• The company is focusing on innovative oncology, supported by the divestiture of its biosimilar assets, including the UDENYCA franchise, to Intas Pharmaceuticals Ltd. for up to $483 million upfront.
• Proceeds from the UDENYCA sale will be used to retire $230 million in convertible debt and $49 million in royalty obligations.
• Coherus anticipates 2024 total net revenues between $255M and $260M.
• Q4 2024 net revenues are expected to be $49M $54M.
• Year-end cash, cash equivalents, and investments are projected to be around $125 million.
• The company's pipeline includes LOQTORZI (toripalimab-tpzi), casdozokitug (IL-27 antagonist), CHS-114 (anti-CCR8), and CHS-1000 (anti-ILT4).
• LOQTORZI is establishing a new standard of care in NPC with recent NCCN guidelines.
• The company expects to initiate a Phase 1b CHS-114/toripalimab combination dose optimization study in 2L gastric cancer and 2L HNSCC in Q1 2025.
• Coherus projects a cash runway exceeding two years post-UDENYCA divestiture, extending past key data readouts expected in 2026.

Sentiment

Score: 7

Explanation: The document presents a positive outlook for Coherus, highlighting strategic transformation, pipeline progress, and financial stability following the UDENYCA divestiture. While risks are acknowledged, the overall tone is optimistic, driven by the potential of the company's immuno-oncology portfolio.

Positives

• The UDENYCA franchise divestiture strengthens the balance sheet and funds the pipeline.
• LOQTORZI is establishing a new standard of care in NPC with recent NCCN guidelines.
• The company has a strong line of sight for target indications with its pipeline assets.
• Casdozokitug has demonstrated monotherapy durable responses and immune activation in cancer patients.
• CHS-114 selectively depletes CCR8+ Tregs, showing proof of mechanism in Phase 1a studies.
• The company has a fully integrated model that maximizes value.

Negatives

• The preliminary 2024 financial information has not been audited and is subject to change.
• The closing of the proposed transactions is subject to various conditions, including shareholder approval and regulatory approvals.
• The company is reliant on the success of its pipeline assets to drive future growth.

Risks

• Uncertainties exist regarding the timing and completion of the UDENYCA franchise sale.
• The company faces risks related to clinical research, commercialization, and regulatory approvals.
• There are uncertainties in executing collaboration agreements and other joint ventures.
• The company's future results could differ materially from forward-looking statements due to various factors, including litigation and market conditions.

Future Outlook

Coherus is focused on advancing its immuno-oncology pipeline and leveraging LOQTORZI in combination therapies to improve patient outcomes and drive long-term revenue growth. The company anticipates key data readouts in 2026 and expects its current cash runway to extend past these milestones.

Industry Context

Coherus's strategic shift towards innovative oncology aligns with the broader industry trend of focusing on targeted therapies and immuno-oncology combinations. The divestiture of biosimilar assets allows the company to concentrate resources on higher-growth areas with significant unmet needs, positioning it to compete with larger pharmaceutical companies in the oncology space.

Comparison to Industry Standards

• LOQTORZI's approval and inclusion in NCCN guidelines position it favorably against competitors in the NPC market.
• The development of casdozokitug and CHS-114 targets novel immune pathways, potentially offering advantages over existing PD-1/PD-L1 inhibitors.
• The company's focus on combination therapies mirrors the strategies of other leading oncology companies, such as Merck (Keytruda) and Bristol-Myers Squibb (Opdivo).
• Coherus's pipeline targets indications with high unmet needs, such as HCC, NSCLC, and gastric cancer, similar to the focus areas of companies like Roche and AstraZeneca.

Stakeholder Impact

• Shareholders will benefit from the strengthened balance sheet and focus on high-growth oncology assets.
• Employees may experience changes due to the divestiture and strategic shift.
• Patients may benefit from the development of new immuno-oncology therapies.
• Suppliers and partners may be affected by the changes in the company's product portfolio.

Next Steps

• Complete the divestiture of the UDENYCA franchise.
• Advance clinical trials for casdozokitug and CHS-114.
• Report final data from Phase 2 trial of casdozokitug/atezolizumab/bevacizumab in 1L HCC at ASCO GI in Q1 2025.
• Initiate Phase 1b CHS-114/toripalimab combination dose optimization studies in 2L gastric cancer and 2L HNSCC in Q1 2025.
• Report Phase 1 CHS-114 monotherapy biopsy data and CHS-114/toripalimab combination safety data in HNSCC in 1H 2025.
• Release complete Coherus Fourth Quarter and Full Year 2024 Financial Results in March 2025.

Key Dates

Keywords

LOQTORZI, UDENYCA, Casdozokitug, CHS-114, Oncology, Biosimilars, Immunotherapy, Pipeline, Divestiture, Coherus BioSciences